## PRISMA-P 2015 Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted - Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 **5**:15

| Section/topic              | ш  | Checklist item  | Information reported |             | Line      |  |  |  |  |  |
|----------------------------|----|---|----------------------|-------------|-----------|--|--|--|--|--|
|                            | #  |   | Yes                  | No          | number(s) |  |  |  |  |  |
| ADMINISTRATIVE INFORMATION |    |   |                      |             |           |  |  |  |  |  |
| Title                      |    |   |                      |             |           |  |  |  |  |  |
| Identification             | 1a | Identify the report as a protocol of a systematic review  |                      |             | 2         |  |  |  |  |  |
| Update                     | 1b | If the protocol is for an update of a previous systematic review, identify as such  |                      |             | NA        |  |  |  |  |  |
| Registration               | 2  | If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract  |                      |             | 53        |  |  |  |  |  |
| Authors                    |    |   |                      |             |           |  |  |  |  |  |
| Contact                    | 3a | Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author   |                      |             | 5-22      |  |  |  |  |  |
| Contributions              | 3b | Describe contributions of protocol authors and identify the guarantor of the review   |                      |             | 281-284   |  |  |  |  |  |
| Amendments                 | 4  | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments |                      | $\boxtimes$ | NA        |  |  |  |  |  |
| Support                    |    |   |                      |             |           |  |  |  |  |  |
| Sources                    | 5a | Indicate sources of financial or other support for the review   |                      |             | NA        |  |  |  |  |  |
| Sponsor                    | 5b | Provide name for the review funder and/or sponsor   |                      |             | NA        |  |  |  |  |  |
| Role of sponsor/funder     | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol  |                      |             | NA        |  |  |  |  |  |
| INTRODUCTION               |    |   |                      |             |           |  |  |  |  |  |
| Rationale                  | 6  | Describe the rationale for the review in the context of what is already known   |                      |             | 69-98     |  |  |  |  |  |



| Section/topic                      | #   | Checklist item  | Information reported |    | Line                             |  |  |  |
|------------------------------------|-----|---|----------------------|----|----------------------------------|--|--|--|
|                                    |     |   | Yes                  | No | number(s)                        |  |  |  |
| Objectives                         | 7   | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)  |                      |    | 97-98                            |  |  |  |
| METHODS                            |     |   |                      |    |                                  |  |  |  |
| Eligibility criteria               | 8   | Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review                   |                      |    | 131-135                          |  |  |  |
| Information sources                | 9   | Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage  |                      |    | 118-120                          |  |  |  |
| Search strategy                    | 10  | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated  |                      |    | Appendix Y                       |  |  |  |
| STUDY RECORDS                      |     |   |                      |    |                                  |  |  |  |
| Data management                    | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review  |                      |    | 155, 162,<br>173,176,<br>181,232 |  |  |  |
| Selection process                  | 11b | State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)   |                      |    | 154-160                          |  |  |  |
| Data collection process            | 11c | Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators  |                      |    | 161-162                          |  |  |  |
| Data items                         | 12  | List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications   |                      |    | 162-168                          |  |  |  |
| Outcomes and prioritization        | 13  | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale  |                      |    | 149-153                          |  |  |  |
| Risk of bias in individual studies | 14  | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis                        |                      |    | 175-180                          |  |  |  |
| DATA                               |     |   |                      |    |                                  |  |  |  |
| Synthesis                          | 15a | Describe criteria under which study data will be quantitatively synthesized   |                      |    | 190-191                          |  |  |  |
|                                    | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau) |                      |    | 186-205                          |  |  |  |



| Section/topic                     | #   | Checklist item  | Information reported |    | Line      |
|-----------------------------------|-----|---|----------------------|----|-----------|
|                                   |     |   | Yes                  | No | number(s) |
|                                   | 15c | Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)                         |                      |    | 185       |
|                                   | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned  |                      |    | 176       |
| Meta-bias(es)                     | 16  | Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies) |                      |    | 226-232   |
| Confidence in cumulative evidence | 17  | Describe how the strength of the body of evidence will be assessed (e.g., GRADE)  |                      |    | 224-233   |

